FY4/18 1Q
Supplementary Materials

September 13, 2017

１．Consolidated Results■Year-on-Year
FY4/17 1Q
results

FY4/18 1Q
results

YoYchange(¥ million)
YoYchange(%)

Net sales

57,81966,095+8,276+14.3

Gross profit

8,954

11,060+2,106+23.5% of net sales

15.5

16.7

6,672

7,096+424+6.4

11.5

10.7

2,281

3,963+1,682

+73.7

3.9

6.0

2,376

4,135+1,759

+74.0

4.1

6.3

1,371

2,120+749

+54.6

2.4

3.2

43.25

66.88

+23.63+54.6

SG&A expenses% of net salesOperating income% of net sales

Ordinary income% of net sales

Profit attributableto owners ofparent% of net sales

Earnings pershare(¥)

Figures in the table are rounded down

■Vs Plan
FY4/18 1Q
plan

FY4/18 1Q
results

Vs planchange(¥ million)
Vs planchange(%)

Net sales

64,25766,095+1,838+2.9

Gross profit% of net sales

10,41011,060

+650

+6.2

16.2

16.7

SG&A expenses% of net sales

7,372

7,096(276)

(3.7)

11.5

10.7

Operating income% of net sales

3,037

3,963+926

+30.5

4.7

6.0Ordinary income% of net sales

3,143

4,135+992+31.6

4.9

6.3

Profit attributableto owners ofparent

1,451

2,120+669+46.1

2.3

3.2

45.79

66.88

+21.09+46.1% of net sales

Earnings pershare(¥)

Figures in the table are rounded down

-1-２. Segment Information（Dispensing Pharmacy Business）■Year-on-Year
FY4/17 1Q
results

FY4/18 1Q
results

YoYchange(¥ million)
YoYchange(%)

Net sales

51,43858,929+7,491+14.6

Gross profit

6,571

8,218+1,647+25.1% of net sales

12.8

13.9

3,226

3,577＋351＋10.9

6.3

6.1

3,345

4,640+1,295+38.7

6.5

7.9

3,437

4,821+1,384+40.3

6.7

8.2

SG&A expenses% of net sales

Operating income% of net sales

Segment income% of net sales

Figures in the table are rounded down

■Vs Plan
FY4/18 1Qplan

FY4/18 1Q
results

Vs planchange(¥ million)
Vs planchange(%)

Net sales

57,30558,929+1,624+2.8

Gross profit

7,608

8,218+610+8.0% of net sales

13.3

13.9

3,505

3,577＋72＋2.1

6.1

6.1

4,102

4,640+538+13.17.2

7.9

4,201

4,821+620+14.8

7.3

8.2

SG&A expenses% of net sales

Operating income% of net sales

Segment income% of net sales

Figures in the table are rounded down-2-3. Segment Information（Drug and Cosmetic Store Business）■Year-on-Year
FY4/17 1Q
results

FY4/18 1Q
results

YoYchange(¥ million)
YoYchange(%)

Net sales

5,246

5,827+581+11.1

Gross profit

1,880

2,105+225+12.0% of net sales

35.8

36.1

2,089

2,077(12)

(0.6)

39.8

35.6

▲209-+236‐

0.5+231‐

SG&A expenses% of net sales

Operating income% of net sales

Segment income% of net sales

27▲194-370.6

Figures in the table are rounded down

■Vs Plan
FY4/18 1Q
plan

FY4/18 1Q
results

Vs planchange(¥ million)
Vs planchange(%)

Net sales

5,610

5,827+217+3.9

Gross profit

2,060

2,105+45+2.2% of net sales

36.7

36.1

2,170

2,077(93)

(4.3)

38.7

35.6+137‐+117‐

SG&A expenses% of net sales

Operating income▲11027-0.5% of net sales

Segment income▲8037-0.6% of net sales
Figures in the table are rounded down-3-4. Sales Verification■Dispensing Pharmacy (YoY）
Net sales
Same store (838)Store openings in theprevious year (200)

Total (1,054)（%）（%）■Dispensing Pharmacy（Vs Plan）
Average
Average
Prescription
Prescription
Net salesprescription
prescription
volumevolumeprice
price+1.0+1.2

Same store (838)+3.2+1.1+2.3+1362.1 +1367.9(1.6)

Store openings in theprevious year (200)+1.6(3.8)+4.8(2.4)

Total (1,054)+2.6(0.2)+2.8+2.0+13.9+16.4‎Versus original plan

■Drug and Cosmetic Store（YoY）
Net sales
Same store (43)Store openings in theprevious year (9)Total (52)（%） ■Drug and Cosmetic Store (Vs Plan）

Average
Number ofspending per
customers
customer

Net sales（%）

Average
Number ofspending per
customers
customer+4.2+2.9

Same store (43)+3.7+1.4+2.3+2571.8 +1890.6+34.2

Store openings in theprevious year (9)+5.4(2.2)+7.8

Total (52)+3.9+1.0+2.8+7.2+11.1+5.6+5.2‎Versus original plan-4-5. Consolidated Balance Sheet■Assets(¥ million)

End-FY4/17 1Q

End-FY4/17

End-FY4/18 1Q

Change26,822
7,621
11,73756,326
14,5709,517
1,273

29,775
9,990
11,66865,42015,365
9,958
1,166

29,5009,656
12,68865,552
15,342
9,871
1,122(275)(334)+1,020+132(23)(87)(44)

27,76628,46428,229(235)

33,30816
35,5582,582
2,084
10,03740,9398
43,1092,435
2,167
10,44340,43816
42,5832,476
2,125
10,763(501)+8(526)+41(42)+320

19,49819,32919,333+4Total assets

82,823
139,149

90,902
156,323

90,146
155,698(756)(625)

Figures in the table are rounded down

Change(¥):End-FY4/18 1Q compared with end-FY4/17

Cash on hand and in banks
Notes and accounts receivable
Inventories
Total current assets
Buildings and structures,net
Land
Lease assets
Total property,plant andequipment
Goodwill
Lease assets
Total intangible fixed assets
Investments in securities
Deferred tax assets
Deposits and guarantees
Total investments and otherassets
Total fixed assets

Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees)
totaled ¥852 million■Liabilities and Net Assets(¥ million)
End-FY4/17 1Q

End-FY4/17

Total liabilities and net assets

38,3208,477
647
67,30013,4481,107
18,40885,7098,682
6,367
38,70853,34053,440139,149

Figures in the table are rounded down

Change(¥):End-FY4/18 1Q compared with end-FY4/17

Accounts payable
Short-term debt
Lease obligations
Total current liabilities
Long-term debt
Lease obligations
Total long-term liabilities
Total liabilities
Common stock
Capital surplus
Retained earnings
Total shareholders’ equity
Total net assets

39,325
7,596
594
72,955
18,254958
23,18896,1448,682
6,367
45,28659,91860,178156,323

End-FY4/18 1Q-5-

41,7798,520
560
73,715
16,376
911
21,26594,981
8,682
6,367
45,82260,45360,717
155,698

Change+2,454+924(34)+760(1,878)(47)(1,923)(1,163)‐‐+536+535+539(625)6. FY4/18 Plan (Consolidated)

FY4/16
results

FY4/17
results

FY4/18plan

Vs planchange(¥ million)
YoYchange (%)

Net sales

234,843

248,110

267,500+19,390+7.8

Gross profit% of net sales

38,53542,092

46,530+4,438

+10.5

16.4

17.0

17.4

SG&A expenses% of net sales

23,91527,52929,930+2,401

+8.7

10.2

11.1

11.2

Operating income% of net sales

14,61914,563

16,600+2,037

+14.0

6.2

5.9

6.2

Ordinary income% of net sales

15,15815,08017,000+1,920

+12.7

6.5

6.1

6.4

7,917

7,949

8,900+951

+12.0

3.4

3.2

3.3

Earnings pershare(¥)

249.69250.71

263.63+11.92+4.8

Annual dividend (¥)

40.00

50.00

50.00

(0.00)(0.0)

Profit attributableto owners of parent% of net sales

Figures in the table are rounded down
Change(¥):FY4/18 plan compared with FY4/17 results
Earnings per share is calculated including new shares issued through a public offering (2,820,000) anda private placement (270,000). The Company plans to issue additional shares (450,000) through a private
placement for a secondary offering using an over-allotment option, but the impact of those shares has notbeen factored into the earnings per share calculation as the payment date is October 3, 2017.

-6-7. Transition of Store Openings■Number of Store Openings in Dispensing Pharmacy Business
FY4/10 FY4/11 FY4/12 FY4/13 FY4/14 FY4/15 FY4/16 FY4/17

FY4/18
1QOrganic

2118273836403227

7M&A335283826119110

182

4Total397448494560616754881

1,066

1,054

FY4/10 FY4/11 FY4/12 FY4/13 FY4/14 FY4/15 FY4/16 FY4/17

FY4/18
1Q

Total number of stores includes ‎temporarily closed stores from FY4/11.

■Number of store openings in Drug and Cosmetic Store Business

Organic

567733590Total

495356615956

52

52

52

Inquiries related to this presentation should be addressed toAIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
http://www.ainj.co.jp/This document may not be reproduced or distributed to any third party without
prior approval of AIN HOLDINGS INC. This document has been prepared for
information purpose only and does not form part of a solicitation to sell orpurchase any securities. Information contained herein may be changed orrevised without prior notice. This document may contain forecasting statements
as to future results of operations. No forecast statement can be guaranteed andactual results of operations may differ from those projected.

-7-